Terfenadine effect on the bronchoconstriction, dermal response, and leukopenia induced by platelet-activating factor.
We have investigated the protective effect of oral terfenadine, a H1 antagonist, on the dermal and pulmonary response, and changes of circulating WBCs to injected and inhaled platelet activating factor. Nine men with mild asthma participated in a double-blind, crossover study using terfenadine, 120 mg, or placebo. Three hours after administration of study drug, pulmonary function was measured, and a PAF challenge was performed. Skin test to histamine and PAF was performed prior to study drug, and 2.5 hours after drug. Circulating WBC count was determined prior to PAF inhalation and during the PAF challenge. There was a significant improvement in pulmonary function on terfenadine. Terfenadine significantly inhibited the wheal and flare response to histamine and the flare response to injected PAF. Terfenadine did not have an effect on the change in circulating WBC count or the change in pulmonary function to inhaled PAF. These results suggest a limited role for endogenous histamine for the effects of PAF.
Allergic Disease Center, Creighton University, Omaha.
R J
RJ
Hopp
R G
RG
Townley
D K
DK
Agrawal
A K
AK
Bewtra
D001249:Asthma / Q000503:physiopathology*; D001985:Bronchial Provocation Tests; D016084:Bronchoconstriction / Q000187:drug effects*; D004311:Double-Blind Method; D006632:Histamine / Q000502:physiology; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced*; D008297:Male; D010972:Platelet Activating Factor / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D012882:Skin Tests; D016593:Terfenadine / Q000494:pharmacology*; D013997:Time Factors
D010972:Platelet Activating Factor; D016593:Terfenadine; D006632:Histamine